The biological journey of aging, a universal yet highly individualized phenomenon, is being illuminated by groundbreaking research from Stanford Medicine, which has identified a critical failure within the immune system as a potential driver of age-related decline across the organism. This extensive investigation, spanning experiments with mice and analyses of human cells, pinpoints a specific impairment in a vital immune cell population that appears to orchestrate a widespread deterioration akin to aging.
At the heart of this discovery are tissue-resident macrophages, a specialized cadre of immune cells that establish permanent residence within the body’s various organs. The research demonstrates that as these macrophages age, their capacity to efficiently clear away other, often senescent, immune cells diminishes significantly. This decline in the body’s cellular waste management system is not an isolated incident but rather a cascade that appears to contribute to the multifaceted process of aging throughout the entire body.
The researchers further elucidated this mechanism by focusing on a single molecular switch – a specific receptor on the surface of these tissue-resident macrophages. When this receptor was experimentally disabled in mice, a remarkable preservation of youthful characteristics was observed across multiple organ systems. This included the brain, heart, skeletal and cardiac muscle, liver, spleen, bone marrow, kidneys, and colon. The receptor in question is known to respond to a hormone intrinsically linked to inflammation and pain, a signaling pathway conserved in both mice and humans.
The implications of targeting this specific receptor were profound. By selectively inactivating it within the tissue-resident macrophage population, the researchers were able to protect the mice from several debilitating conditions commonly associated with chronic inflammation and advanced age. These benefits included mitigating frailty, reducing the accumulation of excess body fat, and improving cardiovascular health. Furthermore, a substantial reduction in cognitive decline was documented, according to insights provided by Dr. Katrin Andreasson, a leading figure in neurology and neurological sciences at Stanford. Dr. Andreasson expressed the significance of these findings, stating, "We’ve been trying to figure out why we age. Now we know at least one big reason for it."
These pivotal findings, detailed in a publication in the prestigious journal Science, with Dr. Andreasson serving as the senior author and Dr. Jessy Tan as the lead author, offer a novel perspective on the pervasive role of chronic, systemic inflammation in aging and its associated health challenges. Moreover, they illuminate a promising avenue for therapeutic intervention, potentially leading to strategies that could decelerate age-related organ deterioration and, consequently, extend the period of healthy lifespan.
To fully appreciate the significance of this discovery, it is essential to understand the natural processes by which the immune system manages aging cells. Neutrophils, the most abundant type of white blood cell, act as the body’s initial rapid response force. Originating in the bone marrow, they circulate in the bloodstream, diligently patrolling for threats such as bacteria, viruses, and fungi. Upon encountering pathogens, neutrophils can deploy a potent arsenal of toxic substances and, in a self-sacrificing act, release web-like structures of biological material to trap and neutralize invaders.
These crucial frontline cells have a relatively short lifespan, typically surviving for around 12 hours, though some can persist for up to 24 hours. A significant majority, approximately 90%, eventually make their way to the liver, spleen, and bone marrow, where they are systematically cleared by other immune cells. This efficient disposal mechanism becomes critically important with advancing age. In older organisms, a substantial proportion of neutrophils that do not encounter pathogens quickly enter a state of senescence – a dysfunctional phase characterized by the release of inflammatory and damaging chemicals that can harm neighboring tissues. The prevalence of these senescent neutrophils increases with age, contributing to a growing burden of cellular damage and inflammation. Dr. Andreasson emphasized this point, noting, "Senescent neutrophils are killing our tissues. Clearance of these cells is essential for preventing chronic inflammation."
Macrophages, the versatile cellular garbage collectors of the body, play a pivotal role in this crucial clean-up operation. Beyond their pathogen-fighting capabilities, macrophages orchestrate the activities of other immune cells and release factors that promote the repair of damaged tissues. A primary function, however, is the removal of dead and dysfunctional cells, a task that is paramount for maintaining tissue health. Dr. Andreasson aptly described them as "the body’s garbage collection crew. A lot of that garbage is defunct cells." It is estimated that the body must clear approximately 100 billion neutrophils every single day, highlighting the immense scale of this cellular waste removal process.
Among the diverse types of macrophages, tissue-resident macrophages are particularly noteworthy. These are exceptionally long-lived cells that migrate to and establish themselves in specific organs during fetal development. Once settled, they remain in their designated locations throughout an individual’s life, adapting to perform specialized functions tailored to the unique environment of each organ. One of their most vital responsibilities is the engulfment of senescent cells, and the current research strongly implicates senescent neutrophils as a particularly significant target of this clearance. Neutrophils begin to exhibit markers of senescence merely 8 to 12 hours after entering circulation, and those that have reached their operational limit, even without encountering a pathogen, are flagged for removal.
The crux of the aging problem, as revealed by this study, lies in the age-related deterioration of the tissue-resident macrophages themselves. Previous work by Dr. Andreasson’s team had indicated that these long-lived immune cells become increasingly susceptible to inflammation as an organism ages, paradoxically contributing to the inflammatory milieu they are meant to combat.
A key mediator in this escalating inflammatory cycle involves prostaglandins, a class of hormones produced by immune cells. Specifically, a subtype known as PGE2 can elicit diverse cellular responses depending on the presence of certain receptors on the cell surface. The EP2 receptor, one such target for PGE2, is strongly associated with the promotion of inflammation, and tissue-resident macrophages are particularly rich in this receptor. PGE2 production typically surges in response to infection, injury, or exposure to toxins, including byproducts of aging. The researchers’ prior findings showed a marked increase in PGE2 levels over time, coinciding with an elevation in EP2 concentrations on tissue-resident macrophages.
This confluence of increased inflammatory signaling and heightened receptor sensitivity creates a detrimental feedback loop. Elevated PGE2 activity continuously stimulates the EP2 receptors on tissue-resident macrophages, progressively impairing their ability to engulf and clear senescent neutrophils. The consequence is a build-up of these aging neutrophils within the bloodstream and tissues, fueling chronic inflammation. Adding to this picture, prior research from Dr. Andreasson’s group demonstrated a gradual decline in the metabolic efficiency of tissue-resident macrophages with age. "Once that starts, there’s a steady decline in a macrophage’s performance," she explained. The new study strongly suggests that the EP2 receptor is instrumental in driving this decline. "We’ve shown that when tissue-resident macrophages don’t have EP2 on their surfaces anymore or when that receptor is plugged up by a drug, this decline doesn’t happen," Dr. Andreasson stated.
To rigorously examine the role of the EP2 receptor, the Andreasson laboratory developed genetically engineered mice. In these animals, the gene responsible for producing EP2 could be selectively deleted from tissue-resident macrophages at a predetermined time. The absence of EP2 effectively restored the macrophages’ phagocytic capacity for neutrophils, thereby reversing the inflammatory disruption previously induced by PGE2.
The researchers then conducted comparative analyses between young adult mice (equivalent to late adolescence or early adulthood in humans) and aged mice (comparable to individuals in their 60s or 70s). A third group consisted of aged mice that had their EP2 gene deleted in tissue-resident macrophages during their "teenage" years. The study identified 71 blood proteins whose levels had significantly shifted in normal aged mice. Strikingly, in the aged mice lacking EP2 in their macrophages, 59 of these proteins remained at levels typically observed in younger animals. The liver, a major hub for tissue-resident macrophage activity and a significant contributor to age-related blood chemistry changes, was a primary source of these normalized proteins. Dr. Andreasson highlighted the liver’s importance, noting, "It’s the central organ determining the body’s metabolic rate."
While normal aged mice exhibited an accumulation of senescent neutrophils in key organs like the liver, spleen, and bone marrow, with smaller increases noted in other examined tissues, the aged mice with EP2-deficient macrophages maintained significantly lower neutrophil levels, mirroring those of younger animals. These physiological improvements were accompanied by visible signs of rejuvenation. The mice appeared younger, leaner, and exhibited enhanced physical fitness compared to their age-matched controls. They displayed reduced visceral fat, increased muscle mass, and their organ function tests yielded results comparable to those of young mice.
Beyond physical attributes, the benefits extended to cognitive and functional capacities. The removal of EP2 from tissue-resident macrophages resulted in a reduction of inflammation across multiple organ systems, including the brain’s hippocampus, a region critically involved in memory and spatial navigation. On physical performance tests assessing speed, balance, and grip strength, the aged mice lacking EP2 performed at levels similar to younger counterparts. Their memory retention was also demonstrably stronger, as evidenced by their proficiency in navigating mazes and recalling previously encountered objects, significantly outperforming similarly aged mice with functional EP2 receptors.
The pursuit of therapeutic strategies now focuses on developing drugs that can specifically target and inhibit EP2 activity. While no approved drug currently offers this precise selectivity, existing medications that modulate PGE2 production, such as nonsteroidal anti-inflammatory drugs (NSAIDs), offer a partial insight. Dr. Andreasson explained that the pain-relieving and anti-inflammatory effects of aspirin and similar drugs stem from their ability to reduce PGE2 synthesis. However, a significant challenge lies in the fact that these broad-acting medications can interfere with other prostaglandins that serve essential physiological roles, and PGE2 itself can have beneficial effects when interacting with different receptors. The ideal therapeutic approach, therefore, would be to selectively block the EP2 receptor responsible for detrimental inflammation without disrupting other vital processes.
To test the feasibility of this targeted approach, the researchers administered an experimental EP2-inhibiting drug to 22-month-old mice for a period of two months. This intervention successfully brought both total neutrophil counts and the prevalence of senescent neutrophils closer to youthful levels. Further experiments utilizing cell cultures confirmed that aging impairs the phagocytic capabilities of tissue-resident macrophages, a deficit that was significantly restored by the EP2-blocking drug.
Crucially, the study extended to human biology, examining a comprehensive database of liver cell data from individuals across different age groups and health statuses. The findings revealed patterns strikingly similar to those observed in mice. Older human livers exhibited increased neutrophil accumulation, a higher proportion of senescent neutrophils, diminished tissue-resident macrophage function, and elevated EP2 activity. These age-related changes were even more pronounced in livers affected by disease. Dr. Andreasson noted the significance of this observation, stating it was "the first time these changes had been observed in human cells." The potential for therapeutic interventions aimed at improving the body’s capacity to clear aging neutrophils offers substantial promise for improving healthspan. "We need to develop a safe drug" that selectively targets EP2 without negatively impacting upstream processes like PGE2 production, Dr. Andreasson concluded.
About the Author
